מבטרה 1400 מ"ג Mabthera 1400 mg s.c. - S.C
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | L01FA CD20 (Clusters of Differentiation 20) inhibitors |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | תת-×¢××¨× - S.C |
| צ×רת ××× ×× | ת×××¡× ×××רק×, SOLUTION FOR INJECTION ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | MabThera subcutaneous formulation is indicated in adults for Non-Hodgkin`s lymphoma (NHL):⢠MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy.⢠MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy.⢠MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkinâs lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. |
| ת×× ×ת:× ×ª×× × ×¡×/××××¨× 1400 ×"× Mabthera 1400 mg s.c. - S.C | |
| ×ת××ת ××× ×× | Posology and method of administration |
| ×ת××××ת × ×× | Contraindications |
| ת×פע×ת ××××× | Undesirable effects |
| ת××××ת ××× ×ª×¨×פת××ת | Interaction with other medicinal products and other forms of interaction |
| ש×××ש ×××ר××× ××× ×§× | Pregnancy and Lactation |
| פר×ק×××× ×××§× | Pharmacodynamic Properties |
| פר×ק×ק×× ×××§× | Pharmacokinetic Properties |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××¨× 1400 ×"× ×ª×ª ×¢××¨× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | F. HOFFMANN-LA ROCHE AG, SWITZERLAND |
| ×©× ××¢× ×ר×ש×× | ROCHE PHARMACEUTICALS (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 08/2014. ר×ש××× ×ת×ר××: 08/2015 |
| ת×ר×× ×¢×××× ××ר×× | 01/03/2025 |
ת××× ×ª ×ר×××
השינוי האחרון נעשה בֹ־1 במרץ 2025 ב־09:48